Aims Peroxisome proliferator-activated receptor-a (PPARa) is a nuclear receptor regulating cardiac metabolism that also has anti-inflammatory properties. Since the activation of inflammatory signalling pathways is considered to be important in cardiac hypertrophy and fibrosis, it is anticipated that PPARa modulates cardiac remodelling. Accordingly, in this study the hypothesis was tested that the absence of PPARa aggravates the cardiac hypertrophic response to pressure overload. Methods and results Male PPARa2/2 and wild-type mice were subjected to transverse aortic constriction (TAC) for 28 days. TAC resulted in a more pronounced increase in ventricular weight and left ventricular (LV) wall thickness in PPARa2/2 than in wild-type mice. Compared with sham-operated mice, TAC did not affect cardiac function in wild-type mice, but significantly depressed LV ejection fraction and LV contractility in PPARa2/2 mice. Moreover, after TAC mRNA levels of hypertrophic (atrial natriuretic factor, a-skeletal actin), fibrotic (collagen 1, matrix metalloproteinase-2), and inflammatory (interleukin-6, tumour necrosis factor-a, cyclo-oxygenase-2) marker genes were higher in PPARa2/2 than in wild-type mice. The mRNA levels of genes involved in fatty acid metabolism (long-chain acyl-CoA synthetase, hydroxyacyl-CoA dehydrogenase) were decreased in PPARa2/2 mice, but were not further compromised by TAC. Conclusion The present findings show that the absence of PPARa results in a more pronounced hypertrophic growth response and cardiac dysfunction that are associated with an enhanced expression of markers of inflammation and extracellular matrix remodelling. These findings indicate that PPARa exerts salutary effects during cardiac hypertrophy.
Introduction
Cardiac hypertrophy is considered to be an adaptive mechanism compensating for a chronic increase in workload. 1 In the long term, however, it can become maladaptive, fibrosis develops, and compensated hypertrophy evolves into cardiac failure, which is characterized by an inadequate cardiac pumping activity. 1, 2 Cardiac hypertrophic growth is associated with neurohormonal as well as metabolic changes. In addition, activation of inflammatory signalling pathways has been considered to promote both cardiac hypertrophy and fibrosis. [3] [4] [5] [6] Conversely, inhibition of inflammation can attenuate the development of cardiac hypertrophy. 7, 8 Several ligand-activated nuclear hormone receptors, including peroxisome proliferator-activated receptor-a (PPARa), have been reported to attenuate the activation of inflammatory signalling pathways 9, 10 and as such may inhibit cardiac hypertrophy and fibrosis. Consistent with this notion, the specific PPARa ligand fenofibrate was able to reduce cardiac hypertrophy both in vitro and in vivo.
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Given the diverse effects of PPARa, the exact mechanism for this anti-hypertrophic effect remains largely elusive, and may involve both stimulatory effects on cardiac fatty acid metabolism 12 as well as anti-inflammatory effects. [13] [14] [15] Accordingly, the aims of this study were to assess if deletion of the PPARa gene affects pressure overload-induced hypertrophy of the heart and to explore which processes may underlie possible PPARa-related differences in the hypertrophic growth response. Hereto, male PPARa2/2 and wild-type mice were subjected to transverse aortic constriction (TAC) and cardiac growth and function were evaluated non-invasively (echocardiography) and invasively [left ventricular (LV) pressure monitoring during a dobutamine stress test] after 4 weeks. To assess whether PPARa deletion affected cardiac hypertrophy, inflammation and fibrosis, gene expression was assessed by quantitative PCR (qPCR). Here we report that (i) absence of PPARa results in a more pronounced hypertrophic growth response, suggesting that PPARa attenuates cardiac remodelling following pressure overload; (ii) mechanical function is depressed in the hypertrophied heart of mice lacking PPARa (iii) deficiency of PPARa is associated with enhanced inflammatory and fibrotic activity in the hypertrophying heart.
Methods

Experimental animals
Male PPARa2/2 mice, 16 backcrossed for more than 10 generations into a pure C57BL6/J background, and age-matched wild-type C57BL6/J mice were included in this study. The genotype was confirmed by qPCR (data not shown). Mice were kept on a 12 h/12 h light/dark cycle in temperature-controlled rooms and had ad libitum access to water and standard lab-chow (Ssniff R/M-H, Ssniff, Soest, Germany). The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Transverse aortic constriction
The surgical procedure of TAC has been previously described. 17 Briefly, 12-14 weeks old mice were anesthetized with xylazine (5 mg/kg s.c.) and ketamine (100 mg/kg i.m.). Anaesthesia was maintained by isoflurane inhalation (1.5-2.5%). After opening the chest, the transverse aorta of PPARa2/2 (n ¼ 23) and wild-type mice (n ¼ 13) was ligated between the truncus brachiocephalicus and the left common carotid artery by tying a 6-0 silk suture against a 25-gauge needle. Sham-operated PPARa2/2 (n ¼ 11) and wild-type mice (n ¼ 9) underwent the same procedure without ligation of the aorta. Animals recovered at 308C for 24 h and were injected with the analgesic buprenorphine (Temgesic; 0.1 mg/kg s.c.). Mice were sacrificed 28 days after TAC or sham operation.
Echocardiographic and haemodynamic measurements
Transthoracic echocardiography was performed 4 weeks after TAC or sham operation using a Hewlett-Packard 15 MHz linear array transducer interfaced with a Sonos 5500 ultrasound machine (Philips, Eindhoven, the Netherlands) as previously described in De Celle et al. 18 Mice were anaesthetized with isoflurane and body temperature was maintained by placing the mice on a heating pad (378C). LV end-diastolic and end-systolic internal diameter (LVIDd and LVIDs), anterior and posterior wall thickness end-diastolic (AWTd and PWTd) and endsystolic (AWTs and PWTs), fractional shortening (FS), ejection fraction (EF), and end-diastolic and end-systolic volume (EDV and ESV) of the LV were measured using data from short-axis (AWT, PWT, LVID, and FS) and parasternal long-axis (EF, EDV, and ESV) views.
Heart rate (HR), LV systolic pressure, and LV contractility (þdP/ dt max ) were also measured 4 weeks after TAC or sham operation under baseline conditions and during a dobutamine stress test as previously described. 18 Briefly, mice were anaesthetized with urethane (2.5 mg/kg i.p.) and a Millar catheter (Mikro-tip 1.4F; SPR-671, Millar Instruments, Houston, TX, USA) was inserted in the right carotid artery. In addition, a fluid-filled catheter was inserted in the femoral artery to determine the pressure-gradient across the aortic constriction. Next, the Millar catheter was advanced into the LV to measure LV pressure and its first derivative þdP/dt (mmHg/s) as a measure of LV contractility. Dobutamine (Sigma, St Louis MO, USA) was infused via a catheter in the vena jugularis with increasing doses up to 0.1 mg/kg/min.
Excision of the heart and cardiac tissue preparation
After completion of the haemodynamic measurements, the heart was excised, the atria were removed, and total ventricular tissue was weighed. Thereafter, ventricles were separated in LV, right ventricle (RV), and septum and snap-frozen for RNA analysis. In a subset of animals, the ventricles were dissected longitudinally. One-half was fixed for 24 h in 4% paraformaldehyde dissolved in phosphatebuffered saline and subsequently embedded in paraffin for further histological analysis. The other half was divided in LV, RV, and septum and snap-frozen in liquid nitrogen. Snap-frozen LV tissue samples were used for RNA analysis.
Histological analysis
Paraffin sections were deparaffinized and subsequently stained with haematoxylin and eosin (H&E) to determine cardiomyocyte shortaxis cross-sectional area (CSA) in the LV. 19 Interstitial fibrosis was measured using Sirius red staining. 20 Stained H&E and Sirius red sections were quantified using Quantimet 570 software (Leica, the Netherlands).
Gene expression
LV tissue was homogenized using an UltraTurrax (Janke&Kunkel, Staufen, Germany) and total RNA was isolated with TRI reagent (Sigma) according to the manufacturer's protocol and complemented with an additional wash step of 70% ethanol to increase the purity of the RNA. Integrity of the RNA was checked by means of the 260 : 280 ratio. cDNA synthesis and qPCR assays were performed as previously described. 21 Primers used for analysis are given in Table 1 . Results were normalized to the geometric mean of three reference genes, i.e. cyclophilin A (CycloA), acidic ribosomal phosphoprotein P0 (ARBP) and hypoxanthine guanine phosphoribosyl transferase (HPRT) according to Vandesompele et al. 22 using qBase software. 23 The expression of these reference genes was not affected by genotype and intervention.
Statistics
Results are presented as mean + SEM. Data were analysed by one-way ANOVA and contrast analysis for multiple comparisons using SPSS 12 software (SPSS Inc.). The dose-dependent curves for dobutamine were compared using two-way ANOVA and a post hoc Bonferonni test. A P-value of less than 0.05 was considered to be statistically significant.
Results
Transverse aortic constriction-induced hypertrophy
None of the PPARa2/2 and wild-type sham-operated animals and of the wild-type animals subjected to TAC died during the course of the study. However, 11 out of 23 (48%) of the PPARa2/2 mice died within 1 h after TAC surgery, indicating that the TAC surgical procedure was poorly tolerated by PPARa2/2 mice. In sham-operated control animals, total ventricular weight (VW) was slightly higher in PPARa2/2 mice than in wild-type mice ( Table 2) . After 28 days of TAC, VW was significantly increased in both wild-type and PPARa2/2 mice. The increase in VW was more pronounced in PPARa2/2 TAC than in wild-type TAC, both when expressed as absolute weight, or when normalized to tibia length or body weight (VW/body weight þ37% vs. þ24%, respectively). In wildtype mice, TAC resulted in an increase in the right carotid artery pressure and a pressure gradient of 40 mmHg across the constriction as measured after 28 days. In PPARa2/2 mice, the pressure-gradient was comparable, but the pressures in both the right carotid artery and femoral artery were lower than in wild-type mice.
Wet lung weight was approximately 10% higher in PPARa2/2 than in wild-type mice. However, when normalized to body weight no significant differences were apparent. Moreover, the ratio between wet and dry lung weight was similar for all groups, indicating that the differences in wet lung weight were not related to pulmonary oedema.
Cardiac dimensions and haemodynamic function
Diastolic and systolic anterior and posterior wall thickness (AWT and PWT) were similar in sham-operated wild-type and PPARa2/2 mice as determined echocardiographically ( Table 3) . TAC significantly increased AWT and PWT in both wild-type and PPARa2/2 mice during diastole. The increase in diastolic AWT and PWT was more pronounced in PPARa 2/2 TAC animals. Histological examination of H&E-stained LV tissue sections revealed that the cardiomyocyte CSA tended to be larger in sham-operated PPARa2/2 mice when compared with wild-type mice (P ¼ 0.078) (Figure 1 ). CSA significantly increased in both PPARa2/2 mice and in wild-type mice after TAC. The increase in CSA after TAC tended to be higher in PPARa2/2 mice when compared with wild-type (P ¼ 0.081).
In sham-operated animals, the diastolic and systolic LV internal diameter (LVIDd and LVIDs) of PPARa2/2 mice were slightly, but significantly, larger when compared with wild-type mice. LVIDd and LVIDs did not increase in wild-type animals after TAC. However, LVIDs of PPARa2/2 TAC mice was 9% larger than that of PPARa2/2 sham mice. In wildtype mice, EF and FS were not affected by TAC (Figure 2A and B). In PPARa2/2 mice, however, TAC resulted in a significant decline of both EF and FS.
Invasive haemodynamic analysis showed that LV systolic pressure and þdP/dt max did not differ between sham- Indicates statistically significant difference compared with corresponding wild-type animals (P , 0.05).
operated wild-type and PPARa2/2 mice ( Figure 2C and D) . TAC was associated with a significantly higher LV systolic pressure in wild-type mice, but not in PPARa2/2 mice, suggesting that the hearts of PPARa2/2 mice were unable to cope with the increase in afterload to which they were exposed for 28 days. The þdP/dt max also was lower in PPARa2/2 mice when compared with wild-type mice after TAC. When hearts were stressed with dobutamine, the increase in þdP/dt max was less in PPARa2/2 sham mice than in wild-type sham mice ( Figure 3A) . In wild-type mice TAC did not influence the dobutamine dose-dependent increase in þdP/dt max . In contrast, in PPARa2/2 mice subjected to TAC þdP/dt max was further compromised. At the highest dobutamine dose tested, þdP/dt max was almost 20% lower in PPARa2/2 TAC than in wild-type TAC mice. Heart rate (HR) was similar for all groups under basal conditions as wells as after maximal stimulation with dobutamine ( Figure 3B ).
Gene expression
The mRNA level of hypertrophic marker genes ANF and a-skeletal actin (a-SKA) was similar in both sham-operated groups ( Figure 4A and B) . TAC increased ANF and a-SKA mRNA after 28 days both in wild-type and PPARa2/2 mice. The increase in ANF and a-SKA mRNA was more pronounced in PPARa2/2 mice than in wild-type mice, although in the case of a-SKA the difference did not reach the level of statistical significance.
To investigate whether TAC is accompanied by increased cardiac expression of inflammatory marker genes, mRNA levels of the pro-inflammatory cytokines interleukin-6 (IL-6), tumour necrosis factor-a (TNF-a), cyclo-oxygenase-2 (COX-2), and monocyte chemo-attractant protein-1 (MCP-1) were determined ( Figure 4C-F ) . Inflammatory gene expression was comparable in sham-operated PPARa2/2 and wild-type mice. After TAC, IL-6 and COX-2 mRNA were unaltered in wild-type mice, but were markedly increased in PPARa2/2 animals. TNF-a mRNA levels also tended to increase in PPARa2/2 TAC animals (P ¼ 0.093). The mRNA level of MCP-1 was affected neither in wild-type mice nor in PPARa2/2 mice subjected to TAC.
As markers for fibrosis, we evaluated the expression of collagen 1 (Col1) and matrix metalloproteinase 2 (MMP-2). The expression of these fibrotic markers was similar in the two sham groups. TAC led to a substantial increase of Col1 and MMP-2 expression in PPARa2/2 mice, but not in wildtype mice ( Figure 4G and H) . Histological staining for fibrosis, however, did not reveal significant differences in fibrotic area (averaging 2% of total tissue area) related to genotype or in response to TAC (data not shown).
As anticipated, the mRNA level of PPAR-responsive genes involved in fatty acid metabolism, e.g. Acyl-CoA synthetase long-chain family member 1 (Acsl1) and the b-oxidation enzyme hydroxyacyl-Coenzyme A dehydrogenase (Hadha) was decreased in PPARa2/2 mice. The expression of both genes was not affected by TAC ( Figure 4I and J).
Discussion
In this study, we demonstrate that the absence of PPARa is associated with a more pronounced hypertrophic response of the murine heart following pressure overload. The increased hypertrophy is accompanied by decreased haemodynamic cardiac function as deduced from echocardiographic analysis and dobutamine stress tests. Moreover, gene expression analysis reveals that fibrotic and inflammatory responses are enhanced in the hearts of PPARa2/2 mice subjected to TAC. The collective findings indicate that loss of PPARa activity is detrimental for the heart when subjected to a chronic increase in workload and suggest that the enhanced cardiac inflammatory response contributes to this negative effect.
Functional characterization of PPARa2/2 mice
The PPARa2/2 mouse is a well-established murine model to study the role of PPARa in lipid metabolism and the relation between changes in lipid handling and disease progression. [24] [25] [26] At first sight, these mice develop normally and do not show phenotypical abnormalities. However, after imposition of stress, e.g. in response to a metabolic challenge or exercise, or during ageing, phenotypical differences become readily apparent particularly in tissues with high oxidative capacity such as the heart. 25 ,27,28 LVIDd, LV internal diameter during diastole; LVIDs, LV internal diameter during systole; AWTd, anterior wall thickness during diastole; AWTs, anterior wall thickness during systole; PWTd, posterior wall thickness during diastole; PWTs, posterior wall thickness during systole; EDV, end-diastolic volume; ESV, end-systolic volume. In the present study no differences were observed in baseline cardiac performance of sham-operated wild-type and PPARa2/2 mice. A number of studies reported that cardiac function is already compromised under basal, unstressed conditions as reflected by a reduced fractional shortening, 29, 30 or a decline in developed pressure of ex vivo perfused hearts. 29 Other studies reported no change in baseline haemodynamic performance of ex vivo perfused PPARa2/2 hearts. 31, 32 However, when the workload was increased acutely, the myocardial ATP content dropped and cardiac function rapidly deteriorated. 31 Consistent with this, we show that the imposition of an acute stress in situ via dobutamine infusion, unveils differences in cardiac function between sham-operated PPARa2/2 and wild-type mice.
The oxidation of fatty acids (FA) forms the principal source of ATP for the healthy, beating heart. 33 Confirming the importance of PPARa in the transcriptional control of cardiac FA oxidation capacity, the expression of ratedetermining enzymes involved in FA activation (Acsl1) and mitochondrial b-oxidation (Hadha) is reduced in the hearts of sham-operated PPARa2/2 mice (Figure 4) . Accordingly, it is quite conceivable that loss of PPARa compromises the energy-generating capacity of the cardiac muscle and may explain some of the dobutamine stress-induced functional abnormalities observed in the sham-operated PPARa2/2 mice.
The compromised cardiac function in PPARa2/2 mice has not only been attributed to disturbances in energy production, 31 but also to diminished b-adrenergic responsiveness. 29 The blunted dobutamine response as observed in the present study would fit with the latter notion. Finally, an increased vulnerability to oxidative stress has been invoked as a cause of functional abnormalities. 30 It remains to be established, however, to what extent each of these mechanisms contributes to the impairment of cardiac function under basal condition or after imposition of an acute or chronic stress.
Cardiac hypertrophy in PPARa2/2 mice
In the present study, young male PPARa2/2 and wild-type mice were subjected to a relatively mild chronic increase in afterload as reflected by the modest pressure-gradient created by the TAC (35-40 mm Hg). The chronic increase in workload led to a marked functional impairment of the heart in the PPARa2/2 mice as shown by the decline in EF and FS and the reduced LV systolic pressure and þdP/ dt max . The differences in contractility became even more pronounced when the TAC mice were subjected to a dobutamine stress test.
Interestingly, in sham-operated PPARa2/2 mice, CSA tended to be increased despite the fact that LV wall thickness is unchanged. Very recently, Guellich et al. 30 also reported that CSA was enhanced in 9-month-old PPARa2/ 2 mice, whereas LV weight was not affected. They argued that this was because of loss of cardiomyocytes secondary to the increased oxidative stress to which the hearts of PPARa2/2 mice are exposed. Strikingly, it has also been reported that activation, instead of lack of PPARa is associated with cardiomyocyte necrosis, secondary to enhanced oxidative stress. 34 In the current study, we measured the expression of the putative PPAR-responsive gene heme oxygenase-1, 35 but found no effect of genotype or TAC on the cardiac mRNA level of this anti-oxidant enzyme (data not shown). An alternative explanation could be that the number of muscle cells is lower because of the effect of PPARa on the proliferation of cardiomyocytes during cardiac development and maturation. It is of note that the tendency to increased cardiomyocyte size is not associated with hallmarks of pathological cardiac hypertrophy, such as the shift in myosin heavy chain (MHCa ! MHCb) protein isoform, 30 or increased mRNA expression of ANF or a-SKA (Figure 4) .
The chronic imposition of pressure overload for 4 weeks led to a more pronounced cardiac hypertrophy in mice lacking PPARa, as shown by the substantially increased LV mass and the increase in LV wall thickness Figure 3 Left ventricular (LV) contractility and heart rate in wild-type and PPARa2/2 mice after transverse aortic constriction (TAC). (A) LV contractility and (B) heart rate were measured during increasing doses of dobutamine infusion in PPARa2/2 and wild-type mice 28 days after TAC. Results are expressed as mean + SEM of n ¼ 8-11 mice per experimental group. Asterisk (*) indicates that curve is statistical significant different when compared with corresponding sham-operated animals (P , 0.05). Hash (#) indicates that curve is statistical significant different when compared with wild-type TAC animals (P , 0.05). (echocardiography). After TAC, CSA also tended to be larger in PPARa2/2 mice than in wild-type mice (P ¼ 0.081). It should be noted, however, that the relative increase in CSA in the PPARa2/2 and wild-type mice was comparable (17%) because of the fact that, as discussed earlier, CSA was somewhat bigger in sham-operated PPARa2/2 mice compared with wild-type mice. Nonetheless, in line with the larger increase in cardiac mass after TAC, the rise in cardiac ANF and a-SKA expression was more pronounced in the PPARa2/2 mice, which also points to an enhanced hypertrophic response in the PPARa2/2 mice. The more pronounced hypertrophic response cannot be explained by differences in blood pressure. In fact, corroborating other studies, 27, 30 mean arterial pressure as measured under basal conditions in awake animals was even slightly lower (210%) in PPARa2/2 mice than in wild-type animals (data not shown). Collectively, these findings indicate that the absence of PPARa enhances pathological hypertrophy of the heart after imposition of pressure overload. This conclusion is supported by earlier studies showing that activation of PPARa via the administration of isoformspecific ligands blunts the hypertrophic response both of the heart in situ and in isolated cardiomyocytes. For example, fenofibrate was able to reduce endothelin-1-induced cardiomyocyte enlargement and protein synthesis. 36, 37 In the in vivo setting, treatment with fenofibrate normalized cardiac dimensions and FS in Dahl salt-sensitive rats and in mice subjected to TAC. 15, 38 Consistent with previous results in mildly hypertrophic hearts of rats subjected to abdominal aortic constriction, 39 the TAC-induced cardiac hypertrophy in wild-type mice was not associated with a diminished expression of FA-handling genes. Likewise, in the myocardium of PPARa2/2 mice, the already reduced expression of these genes did not diminish further after TAC. It cannot be excluded that the chronic increase in afterload may gradually exhaust the already compromised energy-generating capacity of the cardiac muscle cells of the PPARa2/2 mice and, in this way, contribute to the observed cardiomyopathic changes.
The beneficial effect of PPARa activation on LV remodelling has also been attributed to the interference of PPARa with pro-inflammatory pathways converging on activator protein-1 (AP-1) and nuclear factor-kB (NF-kB), which are activated during hypertrophy.
14,36 PPARa activation was Figure 4 Continued.
indeed associated with a decrease in both AP-1 and NF-kB DNA-binding activity in ET-1-treated neonatal rat cardiomyocytes and angiotensin II (AngII)-infused rats, respectively. 14, 36 By inference, this would imply that in hearts devoid of PPARa inflammatory signalling pathways become more activated. Indeed, the current findings show that pro-inflammatory cytokines like IL-6, TNF-a, and the inducible form of cyclo-oxygenase (COX-2), the expression of which are under control of NF-kB, are more upregulated in the hearts of PPARa2/2 mice subjected to TAC than in wildtype mice. It has previously been demonstrated that activation of NF-kB is associated with an increased hypertrophic growth response. 40, 41 Moreover, targeted deletion or pharmacological inhibition of NF-kB, and hence the inflammatory response, attenuated cardiac hypertrophy in vivo. 7, 8 Furthermore, the expression of markers of extracellular matrix (ECM) remodelling, i.e. Col1 and MMP-2 was enhanced in PPARa2/2 mice. Sirius red staining, however, did not show changes in total collagen content in the affected hearts suggesting that, despite the enhanced ECM remodelling, collagen synthesis was still in balance with its degradation. The mRNA findings indicate that, in addition to interfering with the inflammatory pathway, PPARa modulates ECM remodelling. This notion fits with the observation that the in vivo administration of synthetic PPARa ligands to rats attenuates AngII-induced cardiac fibrosis. 14 
Conclusion
The present findings show that the absence of PPARa results in a more pronounced hypertrophic growth response and signs of functional deterioration, associated with an enhanced expression of markers of inflammation and extracellular matrix remodelling. By inference, this implies that in the normal heart, PPARa attenuates pathological cardiac remodelling and, hence, mitigates the functional decline following pressure overload of the affected myocardium.
